市場調査レポート

商品コード

1687590

線維筋痛症治療薬市場規模、シェア、成長分析：薬剤クラス別、診断方法別、投与経路別、薬剤タイプ別、治療チャネル別、流通チャネル別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Fibromyalgia Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Diagnosis Method, By Route of Administration, By Drug Type, By Treatment Channel, By Distribution Channel, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年03月18日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の線維筋痛症治療薬市場規模は2023年に35億米ドルと評価され、予測期間（2025-2032年）のCAGRは8.2%で、2024年の37億9,000万米ドルから2032年には71億1,000万米ドルに成長する見通しです。

線維筋痛症は、世界の成人の約2％が罹患する慢性疼痛疾患であり、広範な疼痛、疲労、睡眠障害や認知障害のような付加的症状を通じて現れ、女性における有病率が顕著に高いです。治療法はないが、症状管理を改善し、罹患者の生活の質を高めるための様々な治療戦略が存在します。これらの治療戦略は、薬物療法、生活習慣の改善、非薬物療法を統合したもので、疼痛の緩和、睡眠の質の改善、認知機能の問題への対処を目的としています。線維筋痛症は複雑であるため、集学的な治療アプローチが必要であり、多くの場合、各個人のユニークなニーズに合わせてカスタマイズされ、この多面的な病態を効果的に管理するための個別化治療の重要性が強調されています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Pfizer Inc.（USA）
AbbVie Inc.（USA）
Eli Lilly and Company（USA）
F. Hoffmann-La Roche Ltd.（Switzerland）
GlaxoSmithKline plc（UK）
Aptinyx Inc.（USA）
Tonix Pharmaceuticals Holding Corp.（USA）
Virios Therapeutics（USA）
Astellas Pharma Inc.（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
Boehringer Ingelheim GmbH（Germany）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
Bristol-Myers Squibb Company（USA）
Takeda Pharmaceutical Company Limited（Japan）
Sun Pharmaceutical Industries Ltd.（India）
Mylan N.V.（USA）
Lupin Limited（India）

結論と提言

Product Code: SQMIG35A2821

Global Fibromyalgia Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.79 billion in 2024 to USD 7.11 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

Fibromyalgia, a chronic pain disorder that affects approximately 2% of adults globally, manifests through widespread pain, fatigue, and additional symptoms like sleep disturbances and cognitive difficulties, with a notably higher prevalence in women. Although there is no cure, various treatment strategies exist to improve symptom management and enhance the quality of life for those affected. These strategies integrate medications, lifestyle changes, and non-pharmacological therapies, aiming to alleviate pain, improve sleep quality, and tackle cognitive issues. The complexity of fibromyalgia necessitates a multidisciplinary treatment approach, often customized to meet the unique needs of each individual, highlighting the importance of personalized care in effectively managing this multifaceted condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fibromyalgia Treatment Market Segments Analysis

Global Fibromyalgia Treatment Market is segmented by Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User and region. Based on Drug Class, the market is segmented into Antidepressants, Antiepileptics, Muscle Relaxants and Others. Based on Diagnosis Method, the market is segmented into Blood Tests and Physical Examination. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Drug Type, the market is segmented into Branded and Generic. Based on Treatment Channel, the market is segmented into Hospitals, Clinics and Homecare. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Adults and Pediatrics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fibromyalgia Treatment Market

The global fibromyalgia treatment market is primarily driven by the rising incidence of fibromyalgia across the globe. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that around five million adults in the United States are affected by this condition, with a staggering 80 to 90 percent of patients being women. This gender disparity highlights the significant toll fibromyalgia takes on women. As awareness surrounding the condition grows and diagnostic methods advance, more cases are being identified globally. Additionally, the limited number of specifically approved medications, currently just three, has led to increased dependence on off-label and generic treatments, further influencing market dynamics. The expiration of patent protections for Lyrica in June 2019 has also introduced generic alternatives, intensifying competition and impacting overall market growth.

Restraints in the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market faces notable restraints due to the limited number of drugs specifically approved for this condition, currently standing at only three options. This scarcity leads to a greater reliance on off-label medications and generic antidepressants to manage symptoms. Moreover, the expiration of patent protection for Lyrica, a crucial medication for fibromyalgia treatment, in June 2019 has significantly impacted market revenues. The introduction of generic alternatives has intensified competition, which further constrains overall market growth. These factors collectively hinder advancements and limit treatment options available to individuals suffering from fibromyalgia worldwide.

Market Trends of the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market is witnessing a notable trend toward the introduction of innovative therapies, driven by key industry players aiming to enhance their presence. The anticipated launch and approval of novel treatments, such as Galcanezumab by Eli Lilly and Company, highlights a strategic focus on expanding existing drug indications to better address the multifaceted needs of fibromyalgia patients. With Galcanezumab currently undergoing clinical trials for fibromyalgia, its upcoming results may significantly impact market dynamics. This proactive engagement in research and development underscores a growing commitment within the pharmaceutical sector to develop effective solutions, thereby contributing to robust market growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape

Global Fibromyalgia Treatment Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Antidepressants
Antiepileptics
Muscle Relaxants
Others

Global Fibromyalgia Treatment Market Size by Diagnosis Method & CAGR (2025-2032)

Market Overview
Blood Tests
Physical Examination

Global Fibromyalgia Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable
Topical

Global Fibromyalgia Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Branded
Generic

Global Fibromyalgia Treatment Market Size by Treatment Channel & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Homecare

Global Fibromyalgia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Fibromyalgia Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Adults
Pediatrics

Global Fibromyalgia Treatment Market Size & CAGR (2025-2032)

North America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
- US
- Canada
Europe (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptinyx Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonix Pharmaceuticals Holding Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virios Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

線維筋痛症治療薬市場規模、シェア、成長分析：薬剤クラス別、診断方法別、投与経路別、薬剤タイプ別、治療チャネル別、流通チャネル別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Fibromyalgia Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Diagnosis Method, By Route of Administration, By Drug Type, By Treatment Channel, By Distribution Channel, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

線維筋痛症治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：診断方法別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：投与経路別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：薬剤タイプ別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：治療チャンネル別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：流通チャネル別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：エンドユーザー別& CAGR（2025-2032）

線維筋痛症治療薬市場規模：地域別& CAGR（2025-2032）